Clinical & Diagnostic

MSD Completes Acquisition of Eyebiotech Limited, Expands Late-Stage Pipeline with Promising Retinal Disease Treatment

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Eyebiotech Limited (EyeBio). ...

 July 15, 2024 | News

ADM Korea to Submit IND for Niclosamide-Based Combination Therapy for Prostate Cancer

IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024. Niclosamide-based metab...

 July 12, 2024 | News

CUHK Faculty of Medicine Identifies Gut Microbial Markers for Autism Diagnosis

The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) has conducted a large cohort study among 1,627 children with and w...

 July 12, 2024 | News

Thermo Fisher and NCI Join Forces to Accelerate Precision Medicine Trials for AML and MDS

To help accelerate research into new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), Thermo Fisher Scientific Inc. (NYSE: T...

 July 12, 2024 | News

Telix Pharmaceuticals Applauds CMS Proposed Changes to Improve Payments for Diagnostic Radiopharmaceuticals

Telix Pharmaceuticals welcomes proposed changes announced by the Centers for Medicare & Medicaid Services (CMS) for the Hospital Outpatient Prospective...

 July 11, 2024 | News

Andelyn Biosciences Selected by UMass Chan Medical School to Manufacture AAV9-CSA Vector for Cockayne Syndrome Treatment

Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selecte...

 July 11, 2024 | News

Surfix Diagnostics, NKI, and CRCbioscreen Collaborate to Enhance Colorectal Cancer Screening

Surfix Diagnostics alongside the Netherlands Cancer Institute (NKI) and CRCbioscreen, announce a collaboration aimed at enhancing colorectal cancer (CRC) s...

 July 10, 2024 | News

Immorna Biotherapeutics to Launch Phase 1/2 Study of Novel mRNA Therapeutic for Cancer

Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics a...

 July 09, 2024 | News

Hinova Pharmaceuticals Secures FDA Fast Track Designation for HP518 in Treating AR+ Triple-Negative Breast Cancer

Hinova Pharmaceuticals  a leading biopharmaceutical company dedicated to developing innovative cancer therapies, today announced that the U.S. Food an...

 July 08, 2024 | News

XPOVIO® Secures NMPA Approval for Treatment of R/R DLBCL in China, Expanding Its Indications

- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monoth...

 July 08, 2024 | News

Aptamer Group and AstraZeneca Collaborate to Advance Targeted siRNA Delivery for Fibrotic Liver Cells

  Aptamer Group , the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce a new agreem...

 July 05, 2024 | News

APPIS Innovator Program 2024 Winners Announced

    The APPIS Innovator Program 2024 has concluded with an impressive showcase of 49 entries from 21 countries, each addressing critical barrie...

 July 04, 2024 | News

Lilly Forms Strategic Partnership with Radionetics for GPCR-Targeted Radiopharmaceuticals

Provides Lilly access to Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals Radionetics to receive $140 million upfront p...

 July 02, 2024 | News

Bayer and Rad AI Collaborate to Enhance Radiology Operations with Advanced AI Solutions

As experts from around the globe gather at the annual Society for Informatics in Medicine (SIIM) conference, Bayer and Rad AI are announcing a collaboratio...

 June 28, 2024 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close